STMicroelectronics | GenomeWeb


The portable analyzer runs an RT-qPCR-based Ebola assay and takes about 75 minutes to detect the presence of the virus from whole blood.

Affymetrix of Santa Clara, Calif., has received US Patent No. 8,586,312, "Methods of using an array of pooled probes in genetic analysis." The patent describes arrays of polynucleotide probes patterned in three discrete regions.

Veredus Laboratories, a Singapore-based molecular diagnostics company, last week launched VereTrop, a biochip that the firm claims can identify 13 major tropical diseases from a single blood sample, including dengue fever, malaria, chikungunya disease and hand, f

Affymetrix last week launched its Axiom high-density genotyping arrays for genome-wide evaluation of microRNA target sites.

Abbott Laboratories has been awarded US Patent No. 8,099,243, "Methods for quantifying a concentration of a target nucleic acid."
Eric Shain, John Clemens, Tzyy-Wen Jeng, and George Schneider are named as inventors on the patent.

Hahn-Schickard-Gesellschaft of Villingen-Schwenningen, Germany, has received US Patent No.

Roche wins multiple US patents; Life Tech, Stanford, Medical Diagnostic Labs, PositiveID, and STMicroelectronics also awarded US patents.

IP Roundup


STMicroelectronics, Samsung Electronics, DermTech International, University of Maryland, Stanford University, Affymetrix

Based on the firm's PCR and microarray platform, VereFoodborne can detect between 10 and 12 food-borne pathogens simultaneously, including E. coli, Salmonella, Listeria, and Campylobacter.

Sankyo, STMicroelectronics, Canon, Pronucleotein Biotechnologies, and Penn State awarded US patents.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.